ArticleNanomedicine (London, England)2011
Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles.
Article in Nanomedicine (London, England), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 64 citations in OpenAlex.
- Research progress of exosomes used in the Alzheimer's disease treatment.Discover nano · 2025Review
- Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Cell primitive-based biomimetic nanomaterials for Alzheimer's disease targeting and therapy.Materials today. Bio · 2023Review
- Cell-Membrane-Coated Nanoparticles for Targeted Drug Delivery to the Brain for the Treatment of Neurological Diseases.Pharmaceutics · 2023Review
- Using Extracellular Vesicles Released by GDNF-Transfected Macrophages for Therapy of Parkinson Disease.Cells · 2022Article
- Biodistribution of Biomimetic Drug Carriers, Mononuclear Cells, and Extracellular Vesicles, in Nonhuman Primates.Advanced biology · 2022Article
- Extracellular Vesicles as Drug Delivery System for Treatment of Neurodegenerative Disorders: Optimization of the Cell Source.Advanced nanobiomed research · 2021Article
- Delivery of Cinnamic Aldehyde Antioxidant Response Activating nanoParticles (ARAPas) for Vascular Applications.Antioxidants (Basel, Switzerland) · 2021Article
- Macrophage membrane-coated nanocarriers Co-Modified by RVG29 and TPP improve brain neuronal mitochondria-targeting and therapeutic efficacy in Alzheimer's disease mice.Bioactive materials · 2021Article
- Engineering MacrophagesFrontiers in oncology · 2021Review
- Tumor-associated macrophages: Role in the pathological process of tumorigenesis and prospective therapeutic use (Review).Biomedical reports · 2020Review
- Engineered Mesenchymal Stem Cells for Targeting Solid Tumors: Therapeutic Potential beyond Regenerative Therapy.The Journal of pharmacology and experimental therapeutics · 2019Review
- TPP1 Delivery to Lysosomes with Extracellular Vesicles and their Enhanced Brain Distribution in the Animal Model of Batten Disease.Advanced healthcare materials · 2019Article
- Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting.Molecular cancer therapeutics · 2018Article
- Insights on Localized and Systemic Delivery of Redox-Based Therapeutics.Oxidative medicine and cellular longevity · 2018Review
- Macrophage-based therapeutic strategies in regenerative medicine.Advanced drug delivery reviews · 2017Review
- Macrophages with cellular backpacks for targeted drug delivery to the brain.Biomaterials · 2017Article
- Progress in tumor-associated macrophage (TAM)-targeted therapeutics.Advanced drug delivery reviews · 2017Review
- Exosomes as drug delivery vehicles for Parkinson's disease therapy.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
Abstract
backgroundWe posit that cell-mediated drug delivery can improve transport of therapeutic enzymes to the brain and decrease inflammation and neurodegeneration seen during Parkinson's disease. Our prior works demonstrated that macrophages loaded with nanoformulated catalase ('nanozyme') then parenterally injected protect the nigrostriatum in a murine model of Parkinson's disease. Packaging of catalase into block ionomer complex with a synthetic polyelectrolyte block copolymer precludes enzyme degradation in macrophages.
methodsWe examined relationships between the composition and structure of block ionomer complexes with a range of block copolymers, their physicochemical characteristics, and loading, release and catalase enzymatic activity in bone marrow-derived macrophages.
resultsFormation of block ionomer complexes resulted in improved aggregation stability. Block ionomer complexes with ε-polylysine and poly(L-glutamic acid)-poly(ethylene glycol) demonstrated the least cytotoxicity and high loading and release rates. However, these formulations did not efficiently protect catalase inside macrophages.
conclusionNanozymes with polyethyleneimine- and poly(L-lysine)(10)-poly(ethylene glycol) provided the best protection of enzymatic activity for cell-mediated drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.